Beilu Pharmaceutical: Vonoprazan Fumarate Tablets Granted Drug Registration Certificate

BeiLu Pharmaceutical announced that it has recently received the "Drug Registration Certificate" for Vonoprazan Fumarate Tablets issued by the National Medical Products Administration. Vonoprazan Fumarate is a potassium-competitive acid blocker (P-CAB), which can inhibit gastric acid secretion and prevent upper gastrointestinal mucosal damage, mainly used for the treatment of reflux esophagitis, and in combination with appropriate antibiotics to eradicate Helicobacter pylori. According to data from Minet, the domestic sales of Vonoprazan Fumarate Tablets (including urban and county-level public hospitals) in 2025 were approximately 973 million yuan. Vonoprazan Fumarate Tablets have been included in the National Medical Insurance Category B List.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned